<!DOCTYPE html>
<html lang="en">

<head>
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, minimum-scale=1.0, maximum-scale=1.0, initial-scale=1.0, user-scalable=no">
	<meta name="format-detection" content="telephone=no">
	<title>Janssen | Home</title>

    <link href="https://fonts.googleapis.com/css?family=Open+Sans:300,400,600,700|Ubuntu:300,400,500,700&display=swap" rel="stylesheet">
	<link type="text/css" rel="stylesheet" href="css/magnific-popup.css">
	<link type="text/css" rel="stylesheet" href="css/style.css">


</head>

<body data-controller="SiteScroll">
	<main class="main-wrap">

		<!-- Beginning main content section -->
		<section class="main-content-wrap">
		<!-- Beginning hero section -->
			<section class="hero-section pos-rel bg-style" style="background-image: url(img/Group-195.jpg)">
                <div class="bottom-left">
			        <img src="img/Group 521.png" alt="">
			        <div class="tree-img1">
			            <img src="svg/Tree_Image1.svg" alt="">
			        </div>
			    </div>
			    <div class="common-wrap clear">
                    <div class="hero-section-inner">
                        <div class="hero-content">
                            <h1><span>It's time</span><br>to give patients more time</h1>
                        </div>
                        <div class="hero-thum-wrap animate-from-right">
				            <div class="parathumb">
                                <div class="patient-thum">
                                    <img src="svg/456.svg" alt="">
                                </div>
                                <div class="doctor-thum pos-rel">
                                    <img src="svg/Man_Dr.svg" alt="" class="step-1">
                                </div>
                            </div>
                        </div>
                    </div>
			    </div>
			    <div class="right-thum">
			        <img src="img/Group-560.png" alt="">
			    </div>
			</section>
			<!-- //End hero section -->

			<section class="second-section ligh-blue-bg">
                <div class="cloudCon">
                    <div class="cloud-wrap">
                        <div class="cloud-1">
                            <img src="img/Group-524.png" alt="">
                        </div>
                        <div class="cloud-2">
                            <img src="img/Group-524.png" alt="">
                        </div>
                        <div class="cloud-3">
                            <img src="img/Group-524.png" alt="">
                        </div>
                        <div class="cloud-4">
                            <img src="img/Group-524.png" alt="">
                        </div>
                        <div class="cloud-5">
                            <img src="img/Group-524.png" alt="">
                        </div>
                    </div>
                </div>
                <div class="section-bg bg-style" style="background-image: url(img/Group-559.png);"></div>
			    <div class="common-wrap clear">
                    <div class="second-section-inner">
                        <div class="second-section-content" id="fade-it">
                            <h3>It is widely accepted that a diagnosis of mCRPC means a poor prognosis<sup>1</sup></h3>
                            <p>Patients with metastatic castration-resistant prostate cancer (mCRPC) face:</p>
                            <ul>
                                <li>• Median survival less than 3 years</li>
                                <li>• Severe symptoms including bone pain and other skeletal-related events</li>
                                <li>• Significant deterioration in quality of life</li>
                            </ul>
                        </div>
                        <div class="second-section-thum-wrap">
                            <div class="wheel-chair-thum" id="move-it">
                                <img src="img/ItsTime_WalkingStick.png" alt="">
                            </div>
                            <div class="tool-thum">
                                <img src="img/Group-30.png" alt="">
                            </div>
                        </div>
                    </div>
			    </div>
			    <div class="bottom-bg">
			        <img src="img/Group-472.png" alt="">
			        <div class="left-lam">
			             <img src="svg/Light_Post2.svg" alt="">
			        </div>
			    </div>
			    <div class="right-lamp">
			        <img src="svg/Light_Post2.svg" alt="">
			    </div>
			</section>

			<section class="third-section pos-rel">
                <div class="third-section-bg bg-style" style="background-image: url('img/Group-487-copy-3.png')"></div>
			    <div class="common-wrap clear">
			        <div class="third-section-inner">
                       <div class="cloudCon">
                            <div class="cloud-wrap">
                                <div class="cloud-1">
                                    <img src="img/Group-524.png" alt="">
                                </div>
                                <div class="cloud-2">
                                    <img src="img/Group-524.png" alt="">
                                </div>
                                <div class="cloud-3">
                                    <img src="img/Group-524.png" alt="">
                                </div>
                                <div class="cloud-4">
                                    <img src="img/Group-524.png" alt="">
                                </div>
                            </div>
                        </div>
                        <div class="dog-thum" id="move-it1">
                            <img src="img/Group-413.png" alt="">
                        </div>
			            <div class="section-content" id="fadeit">
                            <h3>Before progressing from nmCRPC to mCRPC, patients are usually asymptomatic and have a better quality of life<sup>2</sup></h3>
                            <p>Patients with non-metastatic CRPC (nmCRPC) tend to have good:</p>
                            <ul>
                                <li>• Vitality</li>
                                <li>• Social function</li>
                                <li>• Mental health.</li>
                            </ul>
                        </div>
			        </div>
			    </div>
			</section>
			    <section class="pie-chart-section">
                <div class="left-lamp">
                    <img src="svg/Light_Post2.svg" alt="">
                </div>
			    <div class="common-wrap clear">
			        <div class="pie-chart-content" id="fade-in-piechart">
                        <div class="pie-chart-content-inner clear">
                            <h3>ADT and CAB are most commonly used treatments in nmCRPC<sup>3</sup></h3>
                            <p>Many clinicians in Asia Pacific use traditional treatments such as androgen deprivation therapy (ADT) and conventional combined androgen blockage (CAB)</p>
                            <div class="pie-thum">
                                <img src="svg/pie-thum.svg" alt="">
                            </div>
                        </div>
			        </div>
			    </div>
			    <div class="caution-sign">
			        <img src="img/Group-365.png" alt="">
			    </div>
			</section>
			<section class="data-support" id="3stage-parallax">
                <div class="data-support-inner bg-style" style="background-image: url(img/Group-520.png)">
                    <div class="common-wrap clear">
                       <div class="data-support-inner-content">
                         <div class="man-thum-wrap">
                             <figure class="man-1">
                                 <img src="img/Group-501.png" alt="">
                             </figure>
                             <figure class="man-2">
                                 <img src="img/Group-500.png" alt="">
                             </figure>
                             <figure class="man-3">
                                <img src="img/ItsTime_Seated.png" alt="">
                             </figure>
                         </div>
                          <div class="section-content" id="fade">
                                <h3>But the data to support the role of ADT and CAB is suboptimal<sup>4</sup></h3>
                                <p>ADT alone leads to disease progression to mCRPC in 1–2 years.</p>
                                <p>The clinical efficacy of CAB is also limited, with no significant difference in survival seen between CAB</p>
                          </div>
                       </div>
                    </div>
                </div>
                <div class="left-selves">
                    <img src="img/Group-528.png" alt="">
                    <div class="group-tree-img">
                        <img src="svg/Tob_01.svg" alt="">
                    </div>
                    <div class="bottom-leaf">
                        <img src="svg/Tree_Image.svg" alt="">
                    </div>
                </div>
                <div class="right-leaf">
			        <img src="svg/Tree_Image_4.svg" alt="">
			    </div>
			</section>
			<section class="guideline-section bg-style" id="parallax-clock">
               <div class="left-cabinet" id="parallax-it-desk">
                   <img src="img/Group-508.png" alt="">
                   <div class="left-tree-cabinet-img">
                       <img src="svg/Tree_Image_3.svg" alt="">
                   </div>
               </div>
                <div class="guideline-section-bg bg-style" style="background-image: url(img/Group-558.png)">
                   <div class="screen-wrap">
                        <div class="screen-page-thum" id="parallax-it-computer">
                            <img src="img/computer-screen.png" alt="">
                        </div>
                    </div>
                </div>
                <div class="common-wrap clear">
                    <div class="section-content" id="fade-in">
                        <h3>Clinical guidelines reflect the limited clinical benefit of ADT and CAB in nmCRPC<sup>5</sup></h3>
                        <p>Several key international guidelines have been updated to reflect the limited clinical benefit of using CAB and ADT alone in patients with nmCRPC.</p>
                    </div>
                </div>
                <div class="clock watchwrap">
                  <div class="hour"></div>
                  <div class="minute"></div>
                  <div class="centreelm"></div>
                </div>
			</section>
			<!-- Beginning strong data section -->
			<section class="bg-style bg" style="background-image: url('img/Group-513.png')">
            </section>
			<!-- Beginning strong data section -->

			<!-- Beginning strong data section -->
			<section class="strong-data" style="background-image: url('img/BG-1.png')">
			    <div class="common-wrap clear">
               <div class="strong-content-wrap-info">
               <div class="strong-content-wrap" id="fadein">
                   <div class="strong-content">
                       <h3>Strong data supports the role of novel hormone therapies, in addition to ADT, early in the treatment of nmCRPC<sup>6</sup></h3>
                       <p>e.g. apalutamide + ADT:</p>
                       <p>Pivotal clinical trials in patients with nmCRPC showed:</p>
                       <ul>
                           <li>• <strong>25% reduction in risk of death</strong> compared with placebo + ADT (P=0.0197)<sup>1</sup> </li>
                           <li>• <strong>Two additional years without metastasis</strong> Metastasis-free survival (MFS) of 40.5 months v.s 16.2 months with placebo + ADT (P<0.001)<sup>2*</sup> </li>
                   <li>• <strong>One additional year without a second progression</strong> Second progression free survival (PFS2) extended by 11.8 months versus placebo + ADT (apalutamide + ADT 55.6 months versus placebo + ADT 43.8 months)<sup>**</sup></li>
                           <li>• <strong>45% reduction in risk of secondary progression or death</strong> compared with placebo + ADT after the development of mCRPC (P<0.0001).</li> 
                       </ul>
                   </div>
                   <div class="strong-img">
                      <div class="paper-one animateThis">
                          <figure>
                              <img src="img/paper-1.jpg" alt="">
                          </figure>
                          <hr>
                          <hr>
                          <div class="paper-one-first-content">
                              <span><span class="marker-animation" data-ma_repeat="true">One additional year without a second progression.</span> Second progression free survival (PFS2) extended by 11.8 months versus placebo + ADT (apalutamide + ADT 55.6 months versus placebo + ADT 43.8 months).</span>
                          </div>
                          <hr>
                          <hr>
                          <hr>
                          <div class="paper-one-last-content">
                              <span>45% reduction in risk of secondary progression or death</span>
                          </div>
                          <hr>
                          <hr>
                      </div>
                      <div class="paper-two animateThis">
                          <figure>
                              <img src="img/paper-2.jpg" alt="">
                          </figure>
                             <hr>
                             <hr>
                             <hr>
                             <hr>
                             <hr>
                           <div class="paper-two-first-content">
                              <span><span class="marker-animation-one" data-ma_repeat="true">Two additional years without metastasis.</span> Metastasis-free survival (MFS) of 40.5 months v.s 16.2 months with placebo + ADT (P 0.001)</span>
                          </div>
                          <hr>
                          <hr>
                          <hr>
                          <hr>
                        </div>
                      </div>
                   </div>
               </div>
                </div>
			</section>
			<!-- End strong data section -->

			<!-- Beginning video gallery section -->
			<section class="video-gallery" style="background-image: url('img/Group-556@2x.jpg')">
                <div class="common-wrap clear">
                 <div class="video-galler-info">
                      <h3>Experts agree the treatment goals for nmCRPC patients are to delay metastases and maintain quality of life</h3>
                       <div class="gallery-wrap" style="background-image: url('img/Group 557.png')">
                          <div class="gallery-inner clear">
                               <a href="http://www.youtube.com/watch?v=0O2aH4XLbto" class="gallery-item" id="gallery1">
                                   <img src="img/Professor%20Uemura%20Vid%20Still.png" alt="">
                               </a>
                               <a href="https://www.youtube.com/watch?v=HgPp3qp3Bgo" class="gallery-item" id="gallery2">
                                   <img src="img/Professor%20Merseburger.png" alt="">
                               </a>
                               <a href="http://www.youtube.com/watch?v=0O2aH4XLbto" class="gallery-item" id="gallery3">
                                   <img src="img/Professor%20Chiong.png" alt="">
                               </a>
                               <a href="http://www.youtube.com/watch?v=0O2aH4XLbto" class="gallery-item" id="gallery4">
                                   <img src="img/Professor%20Merseburger.png" alt="">
                               </a>
                               <a href="http://www.youtube.com/watch?v=0O2aH4XLbto" class="gallery-item" id="gallery5">
                                   <img src="img/Professor%20Chiong.png" alt="">
                               </a>
                               <a href="http://www.youtube.com/watch?v=0O2aH4XLbto" class="gallery-item" id="gallery6">
                                   <img src="img/Professor%20Uemura%20Vid%20Still.png" alt="">
                               </a>
                           </div>
                           <div  class="right-doctor-img" id="#gallery1">
                               <img src="svg/Man_Dr_2.svg" alt="">
                           </div>
                       </div>
                   </div>
                    <div class="content-wrap">
                        <div class="content-item-wrap">
                            <article class="article" id="article1">
                                <h2>It’s time</h2>
                                <p>to change the way we treat patients advanced prostate cancer</p>
                            </article>
                            <article class="article" id="article2">
                                <h2>It’s time</h2>
                                <p>to recognize the body of evidence and put it into practice. CAB and ADT are no longer enough in the treatment of nmCRPC.</p>
                            </article>
                            <article class="article" id="article3">
                                <h2>It’s time</h2>
                                <p>to intervene early, using a novel hormone therapy, to give your patients with nmCRPC more time to enjoy life with their family and friends.</p>
                            </article>
                            <div class="btn-wrap">
                                <a href="#" class="btn large-btn blue-btn">LEARN MORE</a>
                            </div>
                        </div>
                        <div class="right-img">
                            <img src="svg/Hourglass-doctor.svg" alt="">
                        </div>
                    </div>
                </div>
			</section>
			<!-- End video gallery section -->
			
			<section class="bottom-section">
			    <div class="common-wrap clear">
			        <p>1 Luo J, et al. Oncology (Williston Park). 2016; 30:336–44. Body A, et al. Aust Prescr. 2018; 41:154–9. Saad F et al. Can Urol Assoc J 2018; 12(9):E415-20</p>
                    <p>2 Albertsen PC et al Urology. 1997;49(2):207-216; discussion 216-207</p>
                    <p>3 Janssen. Data on file</p>
                    <p>4 Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.<br> England J Med. 373(8):737-746. Kyriakopoulos CE et al. J Clin Oncol. 2018(36):1080 -1087. Onukwugha E et al. Urol Oncol. 2018;36(7):340.e23-340.e31</p>
                    <p>5 NCCN guidelines version 3, 2016.  Mottet N, et al. EAU guidelines.<a href="https://uroweb.org/guideline/prostate-cancer/">https://uroweb.org/guideline/prostate-cancer/</a>.<br>   Accessed June 13, 2016.  Basch et al. J. Clin. Oncol. 2014 32(30): 3436-3448.  NICE Pathways <a href="https://pathways.nice.org.uk/">https://pathways.nice.org.uk/</a></p> 
                    <p>6 Small EJ et al. Annals of Oncology 0: 1–8, 2019. Smith MR et al. N Engl J Med 2018;378:1408-18.</p>
			    </div>
			</section>
		</section>
		<!-- //End main content section -->
	</main>
	<script src="js/jquery-3.3.1.min.js"></script>
	<script type="text/javascript" src="js/TweenMax.min.js"></script>
	<script type="text/javascript" src="js/jquery.superscrollorama.js"></script>
    <script src="js/jquery.magnific-popup.min.js"></script>
    <script src="js/jquery.marker-animation.min.js"></script>
    <script type="text/javascript" src="js/function.js" defer></script>

</body>

</html>
